Skip to main content
S&P 5007,541.40-0.51%DOW51,983.98+0.41%NASDAQ25,164.36-1.07%BTC$77,142.00-1.60%ETH$2,258.53-1.35%GOLD$3,958.40-0.28%OIL$96.61+0.16%
Smart Investors Daily
SID Premium
AR

NASDAQ · ARTV

Artiva Biotherapeutics, Inc.

Healthcare · Biotechnology

$4.19

Up+$0.00 (+0.00%)

Updated Nov 3, 2026, 10:57 AM

SID Score

3.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
142.85M
P/E ratio
-1.97
Dividend yield
0.00%
52-week range
$4.00 – $14.53
Volume
954.74K
Avg. volume
1.03M

Price performance · ARTV

ARTV price history

1M range · 0 trading sessions · Daily adjusted prices

ARTV does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest ARTV news

The latest Smart Investors Daily articles mentioning ARTV.

Stock researchCompany · Overview

ARTV research

Overview

Company profile and research snapshot.

Company profile

Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$20.50
Implied upside
—
Analysts
12
ARTV recent ratings
DateFirmRatingTarget
Oct 29, 2026JefferiesHold—
Oct 27, 2026NeedhamHold—
Oct 27, 2026WedbushNeutral—
Oct 2, 2026Cantor FitzgeraldOverweight—
Jun 8, 2026NeedhamBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 27, 2026

Artiva Biotherapeutics Plunges Into Crisis Over Patient Deaths and Possible Liquidation

Artiva Biotherapeutics Inc. (NASDAQ:ARTV) announced it will halt further clinical development of its lead cell therapy candidate, slash roughly 94% of its workforce, and evaluate strategic alternatives. The clinical-stage biotechnology company decided on its cell therapy candidate, AlloNK (AB-101), following an extensive risk-benefit assessment. While the non-genetically modified, allogeneic NK cell therapy demonstrated deep B-cell depletion alongside rituximab in autoimmune trials, extended pat

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By